eligibility_summary
Inclusion: Newly diagnosed dual-expression DLBCL (BCL2≥50%, MYC≥40%), age 18–65, ECOG 0–2, survival ≥6 mo, PET/CT-evaluable disease per Lugano, adequate organ function, LVEF≥50%, negative pregnancy test, consent. Exclusion: special/transformed/CNS disease, prior NHL or cytotoxic/anti‑CD20 therapy, recent trials/live vaccines/cytokines, recent major surgery, active infection (TB/HIV/HBV/HCV), serious comorbidities, drug contraindication/allergy, substance abuse, severe mental illness, noncompliance, cannot swallow.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, single-arm trial in untreated double-expressor DLBCL (MYC ≥40%, BCL2 ≥50%) using rituximab + chidamide + zanubrutinib induction with response-adapted CHOP. Drugs/mechanisms (type): rituximab—anti-CD20 chimeric monoclonal antibody, depletes malignant B cells via CDC/ADCC and apoptosis. Chidamide—oral benzamide class selective HDAC inhibitor (HDAC1/2/3/10), epigenetic modulation promoting apoptosis and immune susceptibility. Zanubrutinib—oral covalent BTK inhibitor, blocks BCR/BTK→NF-κB signaling to reduce B-cell survival. CHOP: cyclophosphamide (alkylating DNA cross-linker), doxorubicin/pirarubicin (anthracycline topoisomerase II inhibitor/DNA intercalator), vincristine (vinca alkaloid microtubule inhibitor), prednisone (glucocorticoid, lympholytic). Targets: CD20+ B cells, BCR/BTK/NF-κB pathway, HDAC-driven epigenetic programs (relevant to MYC/BCL2 overexpression), DNA replication/repair, microtubules, and glucocorticoid receptor pathways.